Skip to search formSkip to main contentSkip to account menu

prucalopride

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
The nonselective 5‐HT4 receptor agonists, cisapride and tegaserod have been associated with cardiovascular adverse events (AEs). 
Review
2011
Review
2011
Background  Although constipation can be a chronic and severe problem, it is largely treated empirically. Evidence for the… 
Highly Cited
2010
Highly Cited
2010
Background  Constipation affects up to 50% of the elderly; this study evaluates the efficacy, safety, and tolerability of the… 
Highly Cited
2010
Highly Cited
2010
BackgroundOpioid-induced constipation (OIC) has negative effects on quality of life (QOL). Prucalopride is a new, selective 5-HT4… 
Highly Cited
2009
Highly Cited
2009
Background  Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively… 
Highly Cited
2008
Highly Cited
2008
BACKGROUND In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5… 
Highly Cited
2008
Highly Cited
2008
Objective: To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5… 
Highly Cited
2007
Highly Cited
2007
Obestatin, encoded by the ghrelin gene may inhibit gastrointestinal (GI) motility. This activity was re‐investigated. 
Highly Cited
2001
Highly Cited
2001
BACKGROUND & AIMS Prucalopride (PRU) is a selective benzofuran 5-hydroxytryptamine(4)-receptor agonist with gastrointestinal and… 
Review
2001
Review
2001